All the news Showing 3 of 3 articles from: Experimental treatments for NASH/NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Two novel treatments show promise in improving biomarkers of NASH pathology EASL / 28 August 2020 'Another swing, another miss' for Gilead as NASH combo flops in phase 2 Fierce Biotech / 16 December 2019 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Gilead press release / 16 December 2019 ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive